Jessica Jensen

Technik-/Wissenschafts-/F&E-Leiter bei POINT Biopharma, Inc. (United States)

44 Jahre

Health Technology

Consumer Services

Commercial Services

Aktive Beziehungen

Name	Geschlecht	Alter	Unternehmensverbindungen	Zusammenarbeit
Joe McCann	M	47	POIT BIOP POINT Biopharma, Inc. (United States) POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million.	5 Jahre
Neil Fleshner	M	60	POIT BIOP POINT Biopharma, Inc. (United States) POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million.	5 Jahre
Allan Silber	M	75	POIT BIOP POINT Biopharma, Inc. (United States) POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million.	5 Jahre
Ari Shomair	M	-	POIT BIOP POINT Biopharma, Inc. (United States) POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million.	-
William Demers	M	66	POIT BIOP POINT Biopharma, Inc. (United States) POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million.	4 Jahre
Gerald Hogue	M	66	POIT BIOP POINT Biopharma, Inc. (United States) POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million.	4 Jahre
Justyna Kelly	F	39	POIT BIOP POINT Biopharma, Inc. (United States) POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million.	3 Jahre
David Mims	M	60	PROGENICS PHARMACEUTICALS, INC.	5 Jahre
Jonathan Goodman	M	56	POIT BIOP POINT Biopharma, Inc. (United States) POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million.	4 Jahre
Margaret Gilmour	F	64	POIT BIOP POINT Biopharma, Inc. (United States) POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million.	4 Jahre
Philip Johnson	M	59	POIT BIOP	1 Jahre
Michael Gottlieb	M	45	POIT BIOP POINT Biopharma, Inc. (United States) POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million.	4 Jahre
Michael Thompson	M	-	POIT BIOP	1 Jahre
Gerry Hogue	M	-	POINT Biopharma, Inc. (United States) POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million.	-
Peggy Gilmour	F	-	POINT Biopharma, Inc. (United States) POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million.	-
Howard M. Glase	M	-	POINT Biopharma, Inc. (United States) POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million.	-
Gordon Brooks	M	-	POIT BIOP	1 Jahre
Chris Anderson	M	-	POIT BIOP	1 Jahre

Mehr sehen

Beziehungs-Chart

Beziehungen zu mehreren Unternehmen

Ehemalige Beziehungen

Name	Geschlecht	Alter	Unternehmensverbindungen	Zusammenarbeit
Mark Robert Baker	M	69	PROGENICS PHARMACEUTICALS, INC.	14 Jahre
Peter J. Crowley	M	65	PROGENICS PHARMACEUTICALS, INC.	10 Jahre
Angelo William Lovallo	M	59	PROGENICS PHARMACEUTICALS, INC.	7 Jahre
Nicole S. Williams	F	79	PROGENICS PHARMACEUTICALS, INC.	12 Jahre
Patrick Fabbio	M	56	PROGENICS PHARMACEUTICALS, INC.	5 Jahre
Rajesh K. Malik	M	65	POIT BIOP	2 Jahre
Bridget Martell	M	58	POIT BIOP	-
Karen Ferrante	M	66	PROGENICS PHARMACEUTICALS, INC.	6 Jahre
Bradley Campbell	M	48	PROGENICS PHARMACEUTICALS, INC.	4 Jahre
Mary Heino	F	64	PROGENICS PHARMACEUTICALS, INC.	-
Yael Margolin	M	70	POIT BIOP	2 Jahre
David Lubner	M	60	POIT BIOP	2 Jahre
Ann MacDougall	F	70	PROGENICS PHARMACEUTICALS, INC.	1 Jahre
Michael Kishbauch	M	75	PROGENICS PHARMACEUTICALS, INC.	6 Jahre
Robert J. Israel	M	67	PROGENICS PHARMACEUTICALS, INC.	21 Jahre
David Scheinberg	M	68	PROGENICS PHARMACEUTICALS, INC.	25 Jahre
Jeffrey D. Summer	M	64	PROGENICS PHARMACEUTICALS, INC.	3 Jahre
Robin Hallett	M	-	POIT BIOP	-
Thomas Strack	M	-	PROGENICS PHARMACEUTICALS, INC.	-
Sherin Al-Safadi	M	-	POIT BIOP	-
Myra Rosario Herrle	M	-	POIT BIOP	2 Jahre
Syed Mahmood	M	-	PROGENICS PHARMACEUTICALS, INC.	-
Daniel Pearlstein	M	-	POIT BIOP	2 Jahre
Aseem Anand	M	-	PROGENICS PHARMACEUTICALS, INC.	-
Chris Horvath	M	-	POIT BIOP	1 Jahre
Donna Husack	F	-	POIT BIOP	3 Jahre
Hagop Youssoufian	M	67	PROGENICS PHARMACEUTICALS, INC.	1 Jahre
Bryce V. Tenbarge	M	51	PROGENICS PHARMACEUTICALS, INC.	-
Asha Das	M	59	PROGENICS PHARMACEUTICALS, INC.	-
Robert Marshall	M	57	PROGENICS PHARMACEUTICALS, INC.	-
Matthew Vincent	M	-	POIT BIOP	1 Jahre
Heinz Christoph Mäusli	M	61	PROGENICS PHARMACEUTICALS, INC.	1 Jahre
Gérard Ber	M	66	PROGENICS PHARMACEUTICALS, INC.	1 Jahre
Nitya G. Ray	M	71	PROGENICS PHARMACEUTICALS, INC.	17 Jahre
Sheldon Hirt	M	60	PROGENICS PHARMACEUTICALS, INC.	1 Jahre
Eric Ende	M	55	PROGENICS PHARMACEUTICALS, INC.	1 Jahre
Melita Sequeira	F	-	POIT BIOP	-

Statistik

Land	Beziehungen	% des Gesamten
Vereinigte Staaten	55	100,00%

Alter der Beziehungen

Aktive

Vergangene

Herr

Frau

Aufsichtsräte

Führungskräfte

Ursprung der Beziehungen

Börse
Insiders
Jessica Jensen
Persönliches Netzwerk